Mitsuhito Sasaki

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto et al. · Journal of Clinical Oncology · 2022 · 107 citations

Medicine, Cancer Biology, Oncology +17

Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial

Akihiro Ohba, Chigusa Morizane, Makoto Ueno et al. · Future Oncology · 2022 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17

Etiology and mortality in severe acute pancreatitis: A multicenter study in Japan

Hideto Yasuda, Masayasu Horibe, Masamitsu Sanui et al. · Pancreatology · 2020 · 53 citations

Medicine, Health Sciences, Internal Medicine +13

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto et al. · Journal of Clinical Oncology · 2024 · 50 citations · Full text

Medicine, Oncology, Pharmacology +16

Development and validation of a tuberculosis prognostic score for smear-positive in-patients in Japan

Nobuyuki Horita, N Miyazawa, Takashi Yoshiyama et al. · The International Journal of Tuberculosis and Lung Disease · 2012 · 44 citations

Public Health, Health Sciences, Infectious Diseases +16